- Report
- August 2022
- 118 Pages
Global
From €4324EUR$4,500USD£3,712GBP
- Report
- December 2020
- 90 Pages
Global
From €4324EUR$4,500USD£3,712GBP
- Drug Pipelines
- January 2020
- 53 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Report
- August 2021
- 113 Pages
Global
From €3200EUR$3,568USD£2,843GBP
- Drug Pipelines
- March 2021
Global
From €1922EUR$2,000USD£1,650GBP
Naldemedine is a medication used to treat opioid-induced constipation (OIC) in adults with chronic non-cancer pain. It is a peripherally-acting mu-opioid receptor antagonist (PAMORA) that works by blocking the action of opioids on the gut, allowing for normal bowel movements. Naldemedine is available in tablet form and is taken orally once daily. It is the only PAMORA approved for the treatment of OIC in the United States.
Naldemedine is marketed by Shionogi Inc. in the United States and by Norgine B.V. in Europe. It is also available in other countries through various generic manufacturers.
The market for naldemedine is growing as more people are being prescribed opioids for chronic pain. The drug is seen as a safe and effective treatment for OIC, and its availability in generic form has made it more accessible to patients.
Companies in the naldemedine market include Shionogi Inc., Norgine B.V., and various generic manufacturers. Show Less Read more
